Filings and Continued Examination

Halifax, Nova Scotia, October 21, 2008 – MedMira Inc., (“MedMira”) (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today that it is broadening its US patent portfolio with new filings related to the Company’s rapid flow-through technology, the core innovation behind its rapid diagnostics. In order to strengthen its overall IP position, the Company has also filed for continued examination on its original US patent application that was allowed in July 2008.

“We believe that our technology is one of our Company’s most valuable assets and as such we are taking further steps to strengthen the IP around it, as we move forward with licensing and partnership opportunities. Additional IP was identified during our review and analysis of our rapid flow-through technology and we are now working with our external team to prepare and file patent applications to protect it,” said Dr. Neeraj Vats, VP of Technology & Intellectual Property, MedMira Inc. “We will also be filing a Request for Continued Examination in order to strengthen our original US patent application, which received a Notice of Allowance from the USPTO earlier this year.”

About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company’s tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company’s tests are sold under the Reveal®, MiraWell®, MiraCare™ and Multiplo™ brands in global markets. MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira’s website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company’s current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

MedMira Contacts:

Dr. James Smith, Investor Relations & Corporate Affairs
Tel: 902-450-1588
Email: ir@medmira.com

Andrea Young, Corporate Communications
Tel. 902-450-1588
Email: media@medmira.com